Navigation Links
China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
Date:2/29/2008

HARBIN, China, Feb. 29 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (''China Sky One Medical'' or ''the Company'') (OTC Bulletin Board: CSKI), a leading manufacturer, marketer, and distributor of over the counter pharmaceuticals for external use in the People's Republic of China (''PRC''), today announced that it has signed an agreement to acquire Heilongjiang Tianlong Pharmaceutical, Inc. (''Tianlong''), an external-use drug manufacturing specialty pharmaceutical company.

Under the terms of the agreement, China Sky One Medical's wholly-owned subsidiary, Harbin Tian Di Ren Medical Science and Technology Company, will acquire 100% of Tianlong's operations for a cash payment $8.0 million and approximately $300,000 of China Sky One Medical's common shares. In exchange, China Sky One Medical will obtain Tianlong's $8.3 million in assets, which include $0.5 million in inventory, land use rights, GMP-certified manufacturing facilities, state-of-the-art production equipment, a research and development center, a portfolio of 69 approved drugs (in 98 forms) and a pipeline of 38 new drugs, all of which have been submitted to the SFDA for approval. The acquisition is expected to close on or before March 31, 2008.

''We expect the synergies of this strategic acquisition to make a significant contribution to our profitability in the coming years. Specifically, Tianlong allows us to broaden our product lines and improve our manufacturing and R&D capabilities. At the same time, we expect to leverage our sales and marketing expertise and the benefits of scale to significantly improve Tianlong's revenues and profitability,'' said Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One Medical, Inc.

In 2007, Tianlong generated revenue of $5.2 million with a net profit margin of 13%. Following the acquisition, China Sky One Medical expects Tianlong to be accretive to earnings, generating revenues of approximately $7.5 million and net pr
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009).... 9 Sutter Health, a family of doc...re service providers, is donating $255,000 to food...cal food banks will share the quarter-million-doll...ables of thousands of families across the north st...artnering with and supporting charitable programs ...
(Date:11/9/2009)... with drugs that inhibit estrogen, , , ...to treat breast cancer and osteoporosis eliminated.... , The drugs also cleared precancerous growths... of cancer in mice with precancerous lesions. ,... cancer/osteoporosis drug raloxifene were given to...
(Date:11/9/2009)...both eye conditions are age-related, researchers s...- Cataract surgery doesn,t appear to speed the pro..., according to a new study that challenges the bel... the other. , "Because both conditions are stro...lso have AMD," wrote Li Ming Dong, of Stony Brook ...
(Date:11/9/2009)... /PRNewswire-FirstCall/ - Hard To Treat Diseases (...at Novartis, a US$41 billion international healthc...N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmace...Switzerland will begin a five-year, $1 billion Chi...atically increase its investment in its China R&am...
(Date:11/9/2009)...ive Cancer Network (NCCN) has posted a draft white...adigm for near-term comparative effectiveness clin...ument introduces the NCCN Comparative Therapeutic ...mpares the risk-versus-benefit of different treatm...ice Guidelines in Oncology(TM). The paper will be ...
Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4
...certain cleaning products reduces lung function, i...IDAY, July 25 (HealthDay News) -- A clean, fresh-s...depending on what type of cleaning and air freshen... (VOC) called 1,4 dicholorobenzene (1,4 DCB), can ...
...BROOK, Ill. July 25, 2008 The American Society ...uidelines on the role of endoscopy in the bariatri...y in the United States and the success in surgical...elines discuss endoscopy in the preoperative patie...
... July 25 BeaconEquity.com announces the,availabil... Investors can view all of the daily trading notes..., Today,s Trade Alerts include: DUSA Pharmaceutic...c. (Nasdaq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX...
...nCotter Releases Results of Fourth Annual Physicia...ey, DETROIT, July 25 Sullivan, Cotter and Associ...of physician on-call pay rates and,practices, the ...ctices and rates paid for 33 physician specialty a...
...ays of Marketing Exclusivity Begins -, CORONA, Ca... WPI ), a leading specialty pharmaceutical,compan...ed commercial,shipment of its Omeprazole Delayed-R...f marketing exclusivity for being the,first to fil...
...McKesson Corporation Executive, Robert J. Reilly, ...c.,( http://www.aethon.com ), the leading develope...istics, today announced that Robert J. Reilly has,... Corporation,s Specialty Pharmacy Division, brings...
Other Medicine News:Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2
(Date:11/9/2009)...PLEASANTON, Calif., Nov. 9 /PRNewswire-FirstCall/ ...leader in device-based mechanical circulatory supp... hearts, said today that it will be participating ...rence on Tuesday, November 10. ,, The presentat...ive officer, will begin at 8 a.m., Pacific Standar...
(Date:11/9/2009)...SAN DIEGO, Nov. 9 Volcan...velopment, manufacture and sales of products for t...ral artery disease, said today that it will be par...cular Conference on Tuesday, November 10. ,, Th...chief executive officer, will begin at 1 p.m., Pac...
(Date:11/9/2009)...BIRMINGHAM, Ala., Nov. 9 ...that it will host an investor conference call at 1...9, to discuss its 2009 third quarter operating res...tely an hour following the conclusion of the confe.../cgi-bin/prnh/20080812/CLTU111LOGO ) ,, Plea...
Breaking Medicine Technology:Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 2Emission capture study funded for paper industry 10353 1Emission capture study funded for paper industry 10353 2Emission capture study funded for paper industry 10353 3Chimpanzees help each other on request but not voluntarily 10350 1Chimpanzees help each other on request but not voluntarily 10350 2SIMNSA is added to the Satori Global Network 26amp 3B 238482 3B in Mexico to Offer U S Employers Cross Border Health Benefit Options 59446 1SIMNSA is added to the Satori Global Network 26amp 3B 238482 3B in Mexico to Offer U S Employers Cross Border Health Benefit Options 59446 2
...LIS, France, Nov. 20 NicOx S.A. (Eurolist:,COX) t...as dosed the first,patients in a phase 2 proof of ...Pulmonary Disease (COPD) - see TOPIGEN press relea... the first assessment of TPI 1020,s,potential acti...d novel,anti- inflammatory licensed by TOPIGEN fro...
...strated powerful mean blood pressure reductions of... mm Hg diastolic blood pressure (DBP),at five week...ne in a study of patients with se...BP reductions of 27.1/14.6 mm Hg (SBP/DBP), at 8 .../DBP) reductions, respectively for irbesartan and...
Other Medicine Technology:NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 2NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 3NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 4NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 5NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 6NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 7Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7
COULTER AcT diff2 (Recertified)
mini VIDAS - Recertified
ACE Alera
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: